Study wrapper · #980
The kisspeptin analog C6 elicits greater tachyphylaxis and transcriptional activation than kisspeptin-10 and -54.
Robert V, Lomet D, Dardente H, et al. Molecular and cellular endocrinology. 2026.
DOI: 10.1016/j.mce.2026.112854PubMed: 42379494
Editor's note
This in vitro pharmacology directly compares kisspeptin-10 and kisspeptin-54 against a synthetic analog, relevant background for how different kisspeptin forms behave at the receptor. Findings are cell-based only and focused on drug-discovery characterization, including the tachyphylaxis (desensitization) seen with continuous stimulation. Useful context rather than a human protocol signal.
Plain-language abstract
In engineered cells expressing the human kisspeptin receptor, a synthetic analog (C6) produced more sustained signaling and stronger desensitization than kisspeptin-10 and kisspeptin-54. The three agonists showed distinct pharmacological profiles.
Related coverage
Supported
Kisspeptin-10/basal LH ratio improves differentiation of central precocious puberty and premature thelarche.
Clinica chimica acta; international journal of clinical chemistryn=——2027
Mixed
Kisspeptin System: A Modulator of Neuroinflammation and Behaviour in Temporal Lobe Epileptic Rats.
Molecular neurobiologyn=——2026
Mixed
Follicular kisspeptin-VEGF axis in polycystic ovary syndrome and ovarian hyperstimulation syndrome.
Journal of assisted reproduction and geneticsn=——2026